BCDA Stock Price, BioCardia Inc Quote, Chart

Market Summary

USD0.370.00

Delayed

0.00%

BCDA Stock Price

View Fullscreen

BCDA RSI Chart

BCDA Valuation

Market Cap

9.9M

Price/Earnings (Trailing)

-0.85

Price/Sales (Trailing)

20.74

EV/EBITDA

0.88

Price/Free Cashflow

-0.99

BCDA Price/Sales (Trailing)

BCDA Profitability

Operating Margin

100.00%

EBT Margin

1125.37%

Return on Equity

721.83%

Return on Assets

-387.38%

Free Cashflow Yield

-100.96%

BCDA Fundamentals

BCDA Revenue

Revenue (TTM)

477.0K

Rev. Growth (Yr)

-87.74%

Rev. Growth (Qtr)

-96.36%

BCDA Earnings

Earnings (TTM)

-11.6M

Earnings Growth (Yr)

31.57%

Earnings Growth (Qtr)

19.5%

Breaking Down BCDA Revenue

Last 7 days

2.8%

Last 30 days

-11.9%

Last 90 days

-19.6%

Trailing 12 Months

-81.7%

How does BCDA drawdown profile look like?

BCDA Financial Health

Current Ratio

0.4

BCDA Investor Care

Shares Dilution (1Y)

32.33%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.4M	425.0K	570.0K	477.0K
2022	1.1M	1.2M	1.3M	1.4M
2021	153.0K	195.0K	982.0K	1.0M
2020	532.5K	473.5K	313.5K	145.0K
2019	642.0K	489.0K	599.0K	710.5K
2018	541.0K	668.0K	622.0K	625.0K
2017	535.0K	503.0K	516.0K	479.0K
2016	946.0K	965.0K	961.0K	576.0K
2015	465.0K	485.0K	510.0K	904.0K
2014	328.0K	364.0K	389.0K	427.0K
2013	89.0K	141.0K	193.0K	268.0K
2012	24.5K	37.0K	49.5K	62.0K
2011	0	0	0	12.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of BioCardia Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 19, 2024	frost phillip md et al	sold	-55,814	0.43	-129,802	-
Dec 16, 2022	frost phillip md et al	bought	1,000,000	1.68	595,238	-
Aug 06, 2019	stertzer simon h	acquired	202,452	3.00	67,484	-
Aug 02, 2019	stertzer simon h	bought	999,996	6.00	166,666	-
Jun 28, 2019	altman peter	bought	5,223	8.705	600	president and ceo
Jun 26, 2019	altman peter	bought	924	9.24	100	president and ceo
Jun 25, 2019	altman peter	bought	5,423	10.846	500	president and ceo
Jun 24, 2019	altman peter	bought	1,094	10.945	100	president and ceo
Jun 20, 2019	altman peter	bought	2,700	9.00	300	president and ceo
Jun 19, 2019	altman peter	bought	4,532	11.33	400	president and ceo

Which funds bought or sold BCDA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	2,000	2,000	-%
Apr 24, 2024	BROWN ADVISORY INC	unchanged	-	-8,509	13,466	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	-1,313	2,514	-%
Apr 19, 2024	GenTrust, LLC	unchanged	-	41.00	232	-%
Apr 15, 2024	Octavia Wealth Advisors, LLC	new	-	5,795	5,795	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	152,474	432,237	-%
Feb 26, 2024	Virtu Financial LLC	new	-	27,000	27,000	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	22,336	22,336	-%
Feb 14, 2024	CITADEL ADVISORS LLC	reduced	-1.71	-8,160	574	-%
Feb 14, 2024	Royal Bank of Canada	new	-	-	-	-%

Are Funds Buying or Selling BCDA?

Are funds buying BCDA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BCDA

No. of Funds

Unveiling BioCardia Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	frost gamma investments trust	4.8%	1,286,454	SC 13D/A
Feb 27, 2024	frost gamma investments trust	6.1%	1,571,179	SC 13D/A
Feb 14, 2024	satterfield thomas a jr	7.87%	1,701,000	SC 13G/A
Feb 06, 2024	frost gamma investments trust	8.8%	1,896,025	SC 13D/A
Feb 02, 2024	francis capital management, llc	0%	0	SC 13G/A
Aug 07, 2023	satterfield thomas a jr	5.6%	1,139,603	SC 13G
May 25, 2023	daly joseph patrick	3.75%	758,540	SC 13D
Feb 13, 2023	francis capital management, llc	5.1%	1,017,719	SC 13G/A
Jan 09, 2023	allen jim l.	6.5%	1,341,782	SC 13D/A
Jan 09, 2023	stertzer simon h	9.3%	1,909,185	SC 13D/A

Recent SEC filings of BioCardia Inc

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	4	Insider Trading
Apr 15, 2024	DEF 14A	DEF 14A
Apr 05, 2024	SC 13D/A	13D - Major Acquisition
Apr 04, 2024	PRE 14A	PRE 14A
Apr 01, 2024	EFFECT	EFFECT
Mar 28, 2024	4	Insider Trading
Mar 27, 2024	10-K	Annual Report
Mar 27, 2024	8-K	Current Report
Mar 27, 2024	S-8	Employee Benefits Plan
Mar 13, 2024	8-K	Current Report

Peers (Alternatives to BioCardia Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

BioCardia Inc News

Latest updates

BioCardia Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-96.4%	13.00	357	43.00	64.00	106	212	974	527	79.00	821	69.00	46.00	46.00	34.00	27.00	38.00	215	194	86.00	216	103
Costs and Expenses	-29.0%	2,097	2,955	3,495	3,574	3,124	3,272	3,470	3,387	3,540	3,529	3,558	3,018	3,544	3,882	3,601	4,647	3,751	3,421	3,848	3,903	3,763
S&GA Expenses	-13.1%	941	1,083	1,181	1,190	924	1,128	1,166	1,201	1,425	1,289	1,196	1,177	1,219	1,408	1,377	1,857	1,544	1,390	1,438	1,631	1,442
R&D Expenses	-38.2%	1,156	1,872	2,314	2,384	2,200	2,144	2,304	2,186	2,115	2,240	2,362	1,841	2,325	2,474	2,224	2,786	2,170	2,007	2,219	2,166	2,205
EBITDA Margin	19.5%	11.43*	9.57*	12.85*	4.02*	4.03*	4.29*	4.59*	4.94*	5.35*	5.64*	28.43*	36.22*	38.28*	17.75*	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	-	-	-	112	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	19.5%	11.25*	9.42*	12.63*	3.96*	3.97*	4.23*	4.54*	4.88*	5.29*	5.47*	27.53*	35.08*	37.02*	17.12*	-	-	-	-	-	-	-
Net Income	19.5%	-2,072	-2,574	-3,424	-3,501	-3,028	-3,057	-2,497	-3,325	-3,461	-2,706	-3,487	-2,969	-2,989	-3,848	-3,573	-4,594	-3,501	-3,792	-3,750	-3,665	-3,642
Net Income Margin	-10.4%	-24.26*	-21.98*	-30.61*	-8.91*	-8.81*	-9.73*	-10.13*	-11.81*	-12.44*	-12.37*	-68.17*	-87.44*	-103.48*	-49.49*	-	-	-	-	-	-	-
Free Cashflow	23.3%	-1,851	-2,412	-3,153	-2,570	-2,999	-2,020	-2,670	-2,942	-3,016	-2,663	-2,893	-1,910	-3,417	-3,627	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-20.3%	2,987	3,747	6,389	7,128	9,793	9,179	11,266	12,840	15,718	17,330	20,218	23,308	23,424	9,502	13,128	4,384	7,678	10,681	2,716	5,157	6,417
Current Assets	-31.0%	1,461	2,116	4,650	5,289	7,864	7,154	9,152	10,661	13,481	17,006	19,741	22,659	22,658	8,590	12,096	3,219	6,378	9,237	1,152	3,528	6,218
Cash Equivalents	-40.1%	1,100	1,835	4,305	4,857	7,363	6,667	8,614	6,700	12,872	15,900	18,543	21,502	21,407	7,392	11,086	2,587	5,585	8,910	517	2,838	5,358
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.00	45.00	5.00	118	141
Net PPE	-17.5%	94.00	114	139	158	170	189	204	195	182	175	184	164	145	161	154	164	181	210	218	175	145
Liabilities	4.2%	4,590	4,407	4,754	5,228	4,901	5,082	4,532	5,471	5,343	3,918	4,545	4,746	4,248	5,389	5,837	5,667	5,308	5,487	4,952	4,339	2,625
Current Liabilities	8.3%	3,608	3,330	3,616	4,000	3,585	3,684	3,054	3,913	3,712	-	-	-	4,248	4,320	4,551	4,510	4,003	4,044	4,066	3,323	2,548
Shareholder's Equity	-Infinity%	-1,603	-	1,635	1,900	4,892	4,097	6,734	7,369	10,375	13,412	15,673	18,562	19,176	4,113	7,291	-	2,370	5,194	-	818	3,792
Retained Earnings	-1.4%	-152,175	-150,103	-147,500	-144,105	-140,604	-137,576	-134,500	137,600	-128,697	-125,200	-122,530	-119,043	-116,074	-113,085	-109,237	-105,664	-101,070	-97,568	-93,776	-90,026	-86,361
Additional Paid-In Capital	0.8%	150,548	149,421	149,142	145,985	145,476	141,655	141,235	139,374	139,055	138,631	138,186	137,588	135,234	117,186	116,516	104,374	103,433	102,716	91,496	90,800	90,148
Shares Outstanding	9.5%	23,667	21,619	21,586	20,202	17,721	17,845	17,652	17,066	16,918	16,868	17,047	16,569	16,297	-	-	-	-	-	-	-	-
Float	-	-	-	48,000	-	-	-	19,800	-	-	-	51,800	-	-	-	20,600	-	-	-	23,227	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	23.3%	-1,851	-2,412	-3,151	-2,560	-2,997	-2,006	-2,645	-2,913	-2,975	-2,643	-2,865	-1,883	-3,417	-3,604	-2,343	-2,993	-3,256	-1,472	-2,252	-2,465	-3,246
Share Based Compensation	-26.7%	184	251	317	278	280	280	304	319	424	437	384	416	619	737	655	941	580	756	696	690	691
Cashflow From Investing	-	-	-	-2.00	-10.00	-2.00	-14.00	-25.00	-29.00	-41.00	-20.00	-28.00	-27.00	-	-23.00	-4.00	-5.00	-2.00	-20.00	-69.00	-55.00	-15.00
Cashflow From Financing	2029.3%	1,119	-58.00	2,601	64.00	3,695	73.00	1,354	-	-	8.00	-66.00	2,005	17,432	-67.00	-	-	-67.00	-	-	-	3,799

BCDA Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Net product revenue	$ 477	$ 1,352
Costs and expenses:
Research and development	7,726	8,834
Selling, general and administrative	4,395	4,419
Total costs and expenses	12,121	13,253
Operating loss	(11,644)	(11,901)
Other income (expense):
Total other income (expense), net	73	(6)
Net loss	$ (11,571)	$ (11,907)
Net loss per share, basic and diluted (in dollars per share)	$ (0.55)	$ (0.67)
Weighted-average shares used in computing net loss per share, basic and diluted (in shares)	21,179,974	17,720,972
Product [Member]
Revenue:
Net product revenue	$ 0	$ 3
Collaboration Agreement [Member]
Revenue:
Net product revenue	$ 477	$ 1,349

BCDA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,103	$ 7,363
Accounts receivable, net of allowance for doubtful accounts of $34 and $11 as of December 31, 2023 and 2022	63	201
Prepaid expenses and other current assets	295	300
Total current assets	1,461	7,864
Property and equipment, net	94	170
Operating lease right-of-use asset, net	1,261	1,588
Other assets	171	171
Total assets	2,987	9,793
Current liabilities:
Accounts payable	890	683
Accrued expenses and other current liabilities	2,385	2,246
Deferred revenue	0	341
Operating lease liability - current	333	315
Total current liabilities	3,608	3,585
Operating lease liability - noncurrent	982	1,316
Total liabilities	4,590	4,901
Commitments and Contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.001 par value, 100,000,000 shares authorized, 23,666,534 and 20,076,773 shares issued and outstanding as of December 31, 2023 and 2022, respectively	24	20
Additional paid-in capital	150,548	145,476
Accumulated deficit	(152,175)	(140,604)
Total stockholders’ equity	(1,603)	4,892
Total liabilities and stockholders’ equity	$ 2,987	$ 9,793

About BioCardia Inc

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

CEO	Dr. Peter A. Altman Ph.D.
WEBSITE	biocardia.com
INDUSTRY	Biotechnology
EMPLOYEES	30

BioCardia Inc Frequently Asked Questions

What is the ticker symbol for BioCardia Inc? What does BCDA stand for in stocks?

BCDA is the stock ticker symbol of BioCardia Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioCardia Inc (BCDA)?

As of Fri Apr 26 2024, market cap of BioCardia Inc is 9.89 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCDA stock?

You can check BCDA's fair value in chart for subscribers.

What is the fair value of BCDA stock?

You can check BCDA's fair value in chart for subscribers. The fair value of BioCardia Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioCardia Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BCDA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioCardia Inc a good stock to buy?

The fair value guage provides a quick view whether BCDA is over valued or under valued. Whether BioCardia Inc is cheap or expensive depends on the assumptions which impact BioCardia Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCDA.

What is BioCardia Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, BCDA's PE ratio (Price to Earnings) is -0.85 and Price to Sales (PS) ratio is 20.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCDA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on BioCardia Inc's stock?

In the past 10 years, BioCardia Inc has provided 0.218 (multiply by 100 for percentage) rate of return.